Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
Last trade$55.64
Day change+$0.26 (+0.47%)
Day range$54.95 – $56.86
Volume734,299
Market cap$3.31B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$3.31B
Price / earnings
—
Price / book
6.67×
Price / sales
12.39×
EV / sales
11.16×
EV / EBITDA
-427.89×
Profitability
Earnings per share
-$0.53
Return on assets
-5.8%
Return on equity
-6.43%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
12.02×
Quick ratio
10.67×
Cash ratio
9.02×
Cash flow
Price / cash flow
116.64×
Price / free cash flow
150.09×
Free cash flow
$22.04M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for AXGN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$75.83M
$69.73M
$61.46M
$59.9M
$60.08M
$56.66M
$48.56M
$49.41M
Cost of revenue
$19.1M
$19.06M
$15.27M
$15.5M
$14.09M
$14.64M
$13.63M
$11.83M
Gross profit
$56.73M
$50.67M
$46.19M
$44.41M
$45.99M
$42.02M
$34.93M
$37.58M
Selling, general and administrative
$46.83M
$44.24M
$41.5M
$41.81M
$36.52M
$33.49M
$30.5M
$28.85M
Research and development
$8.95M
$8.59M
$7.52M
$12.38M
$7.57M
$6.85M
$6.09M
$6.7M
Total operating expenses
$55.78M
$52.83M
$49.02M
$54.18M
$44.08M
$40.35M
$36.59M
$35.56M
Operating income
$955K
-$2.16M
-$2.83M
-$9.77M
$1.91M
$1.67M
-$1.66M
$2.02M
Interest expense
-$1K
-$1K
-$694K
-$1.72M
-$1.76M
-$1.98M
-$2.25M
-$1.8M
Income before taxes
$2.33M
-$1.52M
-$19.58M
-$13.16M
$708K
$579K
-$3.83M
$450K
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
$2.33M
-$1.52M
-$19.58M
-$13.16M
$708K
$579K
-$3.83M
$450K
Net income attributable to common shareholders
$2.33M
-$1.52M
-$19.58M
-$13.16M
$708K
$579K
-$3.83M
$450K
EBITDA
$2.65M
-$438K
-$1.13M
-$8.05M
$3.64M
$3.4M
$134K
$3.72M
Basic earnings per share
$0.04
-$0.03
-$0.38
-$0.28
$0.02
$0.01
-$0.08
$0.01
Diluted earnings per share
$0.04
-$0.03
-$0.38
-$0.31
$0.01
$0.01
-$0.08
$0.01
Recent news
Company coverage with links to the original publishers.
The global nerve repair and regeneration market is projected to grow from USD 10.65 billion in 2025 to USD 20.97 billion by 2031, expanding at an 11.96% CAGR. Growth is driven by rising nerve injuries, advances in neurostimulation technologies, and biomaterial innovations. Neurostimulation devices currently dominate with 58.74% market share, while biomaterials are the fastest-growing segment at 14.01% CAGR. High implant costs and cybersecurity risks remain challenges, with Asia-Pacific expected to record the fastest regional growth.
AxoGen (AXGN) is highlighted as a momentum investment pick with a Zacks Rank #2 (Buy) rating and Momentum Style Score of B. The regenerative medicine company has demonstrated strong price performance, gaining 66.85% over the past month and 143.38% over the past year, significantly outperforming the S&P 500. Recent earnings estimate revisions have also moved upward, with consensus estimates increasing from $0.48 to $0.55 in the past 60 days.
Axogen, Inc. (NASDAQ: AXGN), a peripheral nerve repair solutions company, announced its participation in three investor conferences in November and December 2026, including Canaccord Genuity MedTech Forum, Jefferies Global Healthcare Conference, and Piper Sandler Healthcare Conference. The company will host fireside chats and 1x1 investor meetings at these events, with webcasts available on its investor relations page.
A comparison of two Medical-Instruments sector stocks, Globus Medical (GMED) and AxoGen (AXGN), both holding a Zacks Rank #2 (Buy). While both have improving earnings outlooks, GMED emerges as the superior value option with a forward P/E of 15.64 and Value grade of B, compared to AXGN's forward P/E of 95.86 and Value grade of F.
AxoGen is expected to report Q3 2026 earnings of $0.14 per share with 21.2% revenue growth on October 28, but carries a 0% Earnings ESP with a Zacks Rank #2, making it difficult to predict an earnings beat. Meanwhile, IQVIA is projected to post $3.24 EPS with 6.4% revenue growth, but faces a negative Earnings ESP of -0.09% combined with a Zacks Rank #4 (Sell), suggesting limited upside potential despite a history of beating estimates.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Jan 27, 2010
$1.00
Feb 12, 2010
special
Feb 23, 2005
$0.06
Mar 11, 2005
unknown
Stock splits
Historical share-structure events and their execution dates.